Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase

James W Freeman, R. K. Busch, F. Gyorkey, P. Gyorkey, B. E. Ross, H. Busch

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Tumor nucleoli were treated with polyclonal antisera to normal human tissue nucleoli to block some determinants common to tumor and normal tissue nucleoli. Immunization of mice with these immune complexes resulted in the development of a monoclonal antibody (FB2) to a novel M(r) 120,000 nucleolar proliferation-associated antigen. By indirect immunofluorescence, antibody FB2 produced bright nucleolar staining in a variety of malignant tumors, including cancers of the breast, liver, gastrointestinal tract, genitourinary tract, blood, lymph system, lung, and brain. Although specific nucleolar immunofluorescence was not detectable in most normal tissues, it was detectable in some proliferating nonmalignant tissues including spermatogonia of the testes, ductal regions of hypertrophied prostates, and phytohemagglutinin-stimulated lymphocytes. The M(r) 120,000 antigen was not detectable in 48-h serum-deprived HeLa cells but was readily detectable (within 30 min) following serum refeeding. The M(r) 120,000 antigen was not detected in retinoic acid-treated HL-60 cells following morphological differentiation but was detectable in 48-h phytohemagglutinin-treated lymphocytes. These studies suggest that the M(r) 120,000 antigen is a proliferation-associated antigen which plays a role in the early G1 phase of the cell cycle.

Original languageEnglish (US)
Pages (from-to)1244-1251
Number of pages8
JournalCancer Research
Volume48
Issue number5
StatePublished - 1988
Externally publishedYes

Fingerprint

G1 Phase
Molecular Weight
Antigens
Phytohemagglutinins
Lymphocytes
Neoplasms
Spermatogonia
HL-60 Cells
Lymph
Liver Neoplasms
Indirect Fluorescent Antibody Technique
Tretinoin
Antigen-Antibody Complex
Serum
HeLa Cells
Fluorescent Antibody Technique
Gastrointestinal Tract
Testis
Immune Sera
Prostate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase. / Freeman, James W; Busch, R. K.; Gyorkey, F.; Gyorkey, P.; Ross, B. E.; Busch, H.

In: Cancer Research, Vol. 48, No. 5, 1988, p. 1244-1251.

Research output: Contribution to journalArticle

Freeman, James W ; Busch, R. K. ; Gyorkey, F. ; Gyorkey, P. ; Ross, B. E. ; Busch, H. / Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase. In: Cancer Research. 1988 ; Vol. 48, No. 5. pp. 1244-1251.
@article{7861bf63c09c4b7781125f6f82704404,
title = "Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase",
abstract = "Tumor nucleoli were treated with polyclonal antisera to normal human tissue nucleoli to block some determinants common to tumor and normal tissue nucleoli. Immunization of mice with these immune complexes resulted in the development of a monoclonal antibody (FB2) to a novel M(r) 120,000 nucleolar proliferation-associated antigen. By indirect immunofluorescence, antibody FB2 produced bright nucleolar staining in a variety of malignant tumors, including cancers of the breast, liver, gastrointestinal tract, genitourinary tract, blood, lymph system, lung, and brain. Although specific nucleolar immunofluorescence was not detectable in most normal tissues, it was detectable in some proliferating nonmalignant tissues including spermatogonia of the testes, ductal regions of hypertrophied prostates, and phytohemagglutinin-stimulated lymphocytes. The M(r) 120,000 antigen was not detectable in 48-h serum-deprived HeLa cells but was readily detectable (within 30 min) following serum refeeding. The M(r) 120,000 antigen was not detected in retinoic acid-treated HL-60 cells following morphological differentiation but was detectable in 48-h phytohemagglutinin-treated lymphocytes. These studies suggest that the M(r) 120,000 antigen is a proliferation-associated antigen which plays a role in the early G1 phase of the cell cycle.",
author = "Freeman, {James W} and Busch, {R. K.} and F. Gyorkey and P. Gyorkey and Ross, {B. E.} and H. Busch",
year = "1988",
language = "English (US)",
volume = "48",
pages = "1244--1251",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase

AU - Freeman, James W

AU - Busch, R. K.

AU - Gyorkey, F.

AU - Gyorkey, P.

AU - Ross, B. E.

AU - Busch, H.

PY - 1988

Y1 - 1988

N2 - Tumor nucleoli were treated with polyclonal antisera to normal human tissue nucleoli to block some determinants common to tumor and normal tissue nucleoli. Immunization of mice with these immune complexes resulted in the development of a monoclonal antibody (FB2) to a novel M(r) 120,000 nucleolar proliferation-associated antigen. By indirect immunofluorescence, antibody FB2 produced bright nucleolar staining in a variety of malignant tumors, including cancers of the breast, liver, gastrointestinal tract, genitourinary tract, blood, lymph system, lung, and brain. Although specific nucleolar immunofluorescence was not detectable in most normal tissues, it was detectable in some proliferating nonmalignant tissues including spermatogonia of the testes, ductal regions of hypertrophied prostates, and phytohemagglutinin-stimulated lymphocytes. The M(r) 120,000 antigen was not detectable in 48-h serum-deprived HeLa cells but was readily detectable (within 30 min) following serum refeeding. The M(r) 120,000 antigen was not detected in retinoic acid-treated HL-60 cells following morphological differentiation but was detectable in 48-h phytohemagglutinin-treated lymphocytes. These studies suggest that the M(r) 120,000 antigen is a proliferation-associated antigen which plays a role in the early G1 phase of the cell cycle.

AB - Tumor nucleoli were treated with polyclonal antisera to normal human tissue nucleoli to block some determinants common to tumor and normal tissue nucleoli. Immunization of mice with these immune complexes resulted in the development of a monoclonal antibody (FB2) to a novel M(r) 120,000 nucleolar proliferation-associated antigen. By indirect immunofluorescence, antibody FB2 produced bright nucleolar staining in a variety of malignant tumors, including cancers of the breast, liver, gastrointestinal tract, genitourinary tract, blood, lymph system, lung, and brain. Although specific nucleolar immunofluorescence was not detectable in most normal tissues, it was detectable in some proliferating nonmalignant tissues including spermatogonia of the testes, ductal regions of hypertrophied prostates, and phytohemagglutinin-stimulated lymphocytes. The M(r) 120,000 antigen was not detectable in 48-h serum-deprived HeLa cells but was readily detectable (within 30 min) following serum refeeding. The M(r) 120,000 antigen was not detected in retinoic acid-treated HL-60 cells following morphological differentiation but was detectable in 48-h phytohemagglutinin-treated lymphocytes. These studies suggest that the M(r) 120,000 antigen is a proliferation-associated antigen which plays a role in the early G1 phase of the cell cycle.

UR - http://www.scopus.com/inward/record.url?scp=0023870151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023870151&partnerID=8YFLogxK

M3 - Article

C2 - 3422591

AN - SCOPUS:0023870151

VL - 48

SP - 1244

EP - 1251

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 5

ER -